Interleukin-37 mediates the antitumor activity in hepatocellular carcinoma: Role for CD57+ NK Cells

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Zhao, Jing Jing ^a   Pan, Qiu Zhong ^a   Pan, Ke ^a   Weng, De Sheng ^a   Wang, Qi Jing ^a   Li, Jian Jun ^a   Lv, Lin ^a   Wang, Dan Dan ^a   Zheng, Hai Xia ^a   Jiang, Shan Shan ^a   Zhang, Xiao Fei ^a   Xia, Jian Chuan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD57 ANTIGEN; IL37 PROTEIN, HUMAN; INTERLEUKIN 1;

ANIMAL; APOPTOSIS; C57BL MOUSE; CARCINOMA, HEPATOCELLULAR; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CHEMOTAXIS; DRUG SCREENING; ENZYME IMMUNOASSAY; FEMALE; HUMAN; IMMUNOLOGY; LIVER NEOPLASMS; MALE; METABOLISM; MIDDLE AGED; MORTALITY; MOUSE; NATURAL KILLER CELL; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR CELL CULTURE;

ANIMALS; ANTIGENS, CD57; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CHEMOTAXIS; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; INTERLEUKIN-1; KILLER CELLS, NATURAL; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84902076919     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep05177     Document Type: Article

References (33)

1. Giannelli, G. & Antonaci, S. Novel concepts in hepatocellular carcinoma: from molecular research to clinical practice. J Clin Gastroenterol. 40, 842-846 (2006).
2. Guo, C. L. et al. Associations between infiltrating lymphocyte subsets and hepatocellular carcinoma. Asian Pac J Cancer Prev. 13, 5909-5913 (2012).
3. Murray, C. J. & Lopez, A. D. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet. 349, 1269-1276 (1997).
4. Thomas, M. B. & Zhu, A. X. Hepatocellular carcinoma: the need for progress. J Clin Oncol. 23, 2892-2899 (2005).
5. Yang, J. D., Nakamura, I. & Roberts, L. R. The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. Semin Cancer Biol. 21, 35-43 (2011).
6. Zhao, J. J. et al. Identification of LZAP as a new candidate tumor suppressor in hepatocellular carcinoma. PLoS One. 6, e26608 (2011).
7. Chew, V. et al. Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients. J Hepatol. 52, 370-379 (2010).
8. Kremsdorf, D., Soussan, P., Paterlini-Brechot, P. & Brechot, C. Hepatitis B virusrelated hepatocellular carcinoma: paradigms for viral-related human carcinogenesis. Oncogene. 25, 3823-3833 (2006).
9. Nakamoto, Y., Guidotti, L. G., Kuhlen, C. V., Fowler, P. & Chisari, F. V. Immune pathogenesis of hepatocellular carcinoma. J Exp Med. 188, 341-350 (1998).
10. Akiba, J., Yano, H., Ogasawara, S., Higaki, K. & Kojiro, M. Expression and function of interleukin-8 in human hepatocellular carcinoma. Int J Oncol. 18, 257-264 (2001).
11. Hu, P. et al. Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Mol Immunol. 46, 1654-1662 (2009).
12. Ikeguchi, M. & Hirooka, Y. Interleukin-2 gene expression is a new biological prognostic marker in hepatocellular carcinomas. Onkologie. 28, 255-259 (2005).
13. Jiang, R. et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology. 54, 900-909 (2011).
14. Cressman, D. E. et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science. 274, 1379-1383 (1996).
15. Nakagawa, H. et al. Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int J Cancer. 125, 2264-2269 (2009).
16. Tilg, H. et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology. 103, 264-274 (1992).
17. Wong, V. W. et al. High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer. 124, 2766-2770 (2009).
18. Zhu, A. X. et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol. 27, 3027-3035 (2009).
19. Bulau, A.M. et al. In vivo expression of interleukin-37 reduces local and systemic inflammation in concanavalin A-induced hepatitis. ScientificWorldJournal. 11, 2480-2490 (2011).
20. Dinarello, C. A. Biologic basis for interleukin-1 in disease. Blood. 87, 2095-2147 (1996).
21. Dinarello, C. A. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int Rev Immunol. 16, 457-499 (1998).
22. Nold, M. F. et al. IL-37 is a fundamental inhibitor of innate immunity. Nat Immunol. 11, 1014-1022 (2010).
23. McNamee, E. N. et al. Interleukin 37 expression protects mice from colitis. Proc Natl Acad Sci USA. 108, 16711-16716 (2011).
24. Gao, W. et al. Innate immunity mediated by the cytokine IL-1 homologue 4 (IL-1H4/IL-1F7) induces IL-12-dependent adaptive and profound antitumor immunity. J Immunol. 170, 107-113 (2003).
25. Apte, R. N. & Voronov, E. Interleukin-1-a major pleiotropic cytokine in tumorhost interactions. Semin Cancer Biol. 12, 277-290 (2002).
26. Kuppala, M. B. et al. Immunotherapeutic approach for better management of cancer-role of IL-18. Asian Pac J Cancer Prev. 13, 5353-5361 (2012).
27. Moretta, L. et al. Human NK Cells: From Surface Receptors to the Therapy of Leukemias and Solid Tumors. Front Immunol. 5, 87 (2014).
28. Bannerji, R., Arroyo, C. D., Cordon-Cardo, C. & Gilboa, E. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J Immunol. 152, 2324-2332 (1994).
29. Ha, S. J., Lee, S. B., Kim, C. M., Shin, H. S. & Sung, Y. C. Rapid recruitment of macrophages in interleukin-12-mediated tumour regression. Immunology. 95, 156-163 (1998).
30. Schroten, C. et al. Tumor protection by IL-7 secreting whole cell vaccine is merely mediated by NK1.1-positive cells. J Immunother. 35, 125-130 (2012).
31. Senovilla, L. et al. Trial watch: Prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology. 1, 1323-1343 (2012).
32. van Herpen, C. M. et al. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor. Clin Cancer Res. 11, 1899-1909 (2005).
33. Baginska, J. et al. The Critical Role of the Tumor Microenvironment in Shaping Natural Killer Cell-Mediated Anti-Tumor Immunity. Front Immunol. 4, 490 (2013).